» Articles » PMID: 39312186

Controlling the Redox Chemistry of Cobalt Radiopharmaceuticals

Overview
Specialty Chemistry
Date 2024 Sep 23
PMID 39312186
Authors
Affiliations
Soon will be listed here.
Abstract

The elementally matched Co (t=17.53 h, I=77 %)/Co (t=9.10 h, internal conversion=100 %) radioisotope pair is of interest for development of paired diagnostic/therapeutic radiopharmaceuticals. Due to the accessibility of the Co redox couple, the redox state can be readily modulated. Here, we show that macroscopic and radiochemical redox reactions can be closely monitored and controlled using spectroscopic and radiochemical methods. We employ model systems to inform how to selectively synthesize thermodynamically favored oxidation state coordination complexes. In addition to exogenous oxidants, our data indicates that Co-induced radiolysis of water efficiently and directly drives selective oxidation to the Co species under no-carrier added (n.c.a.) conditions. Our synthetic strategies subsequently stabilize the respective Co or Co species for targeted positron emission tomography imaging in a mouse tumor model.

Citing Articles

Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics.

Ge L, Danielsen M, Nielsen A, Skavenborg M, Langkjaer N, Thisgaard H Molecules. 2025; 30(2).

PMID: 39860082 PMC: 11767697. DOI: 10.3390/molecules30020212.


Controlling the Redox Chemistry of Cobalt Radiopharmaceuticals.

Lin W, Smilowicz D, Joaqui-Joaqui M, Bera A, Zhong Z, Aluicio-Sarduy E Angew Chem Int Ed Engl. 2024; 63(50):e202412357.

PMID: 39312186 PMC: 11609885. DOI: 10.1002/anie.202412357.

References
1.
Lin W, Aluicio-Sarduy E, Houson H, Barnhart T, Tekin V, Jeffery J . Theranostic cobalt-55/58m for neurotensin receptor-mediated radiotherapy in vivo: A pilot study with dosimetry. Nucl Med Biol. 2023; 118-119:108329. PMC: 10121947. DOI: 10.1016/j.nucmedbio.2023.108329. View

2.
Heppeler A, Andre J, Buschmann I, Wang X, Reubi J, Hennig M . Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting. Chemistry. 2008; 14(10):3026-34. DOI: 10.1002/chem.200701264. View

3.
Munteanu C, Suntharalingam K . Advances in cobalt complexes as anticancer agents. Dalton Trans. 2015; 44(31):13796-808. DOI: 10.1039/c5dt02101d. View

4.
Lin W, Smilowicz D, Joaqui-Joaqui M, Bera A, Zhong Z, Aluicio-Sarduy E . Controlling the Redox Chemistry of Cobalt Radiopharmaceuticals. Angew Chem Int Ed Engl. 2024; 63(50):e202412357. PMC: 11609885. DOI: 10.1002/anie.202412357. View

5.
Heffern M, Yamamoto N, Holbrook R, Eckermann A, Meade T . Cobalt derivatives as promising therapeutic agents. Curr Opin Chem Biol. 2012; 17(2):189-96. PMC: 3622775. DOI: 10.1016/j.cbpa.2012.11.019. View